Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema
Astria Therapeutics' STAR-0215 offers revolutionary HAE treatment with superior results and minimal risks. Click here to find ...
KalVista: Upcoming PDUFA, But Not Without Risks
KalVista's sebetralstat shows strong phase 3 results for HAE, but financial concerns and competition make investing cautious. Click here to read more.
2minutemedicine.com8 天
Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary ...
CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...
Pharmabiz15 天
BioCryst launches Orladeyo in Ireland for routine prevention of recurrent attacks of HAE in ...
Research Triangle Park, North Carolina Tuesday, November 19, 2024, 16:00 Hrs [IST] ...
Business Insider16 天
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. U.S. Indication and Important Safety Information INDICATION ORLADEYO ® (berotralstat) is a ...
BioSpace29 天
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI ...
About Sebetralstat Discovered and developed entirely by the scientific team at KalVista, sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE.
Morningstar29 天
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI ...
About Sebetralstat Discovered and developed entirely by the scientific team at KalVista, sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE.